Sometimes gifts in the stock market come from macro volatility. Other times, management offers the gift themselves without meaning to at all. That is what I think has happened with Meta Platforms (Julian Lin is a financial analyst. He finds undervalued companies with secular growth that appreciate over time. His approach is to look for companies with strong balance sheets and management teams in sectors with long growth runways. Julian is the leader of the investing group Best Of Breed Growth Stocks where h ...

- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential - - CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy - - IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema - ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. ...

Limited Time Only: Get $100 Off!Your timing is perfect. We’ve just released our top investment picks for 2026, and for a limited time, you can join High Yield Investor for $100 off.We invest thousands of hours and over $100,000 annually researching the most profitable opportunities—all to bring you high-yield strategies at a fraction of the cost.Our approach has earned us nearly 200 five-star reviews from satisfied members already seeing results.Offer ends soon—join now to claim your $100 discount and start ...

NervGen Pharma Reports Third Quarter Financial Results and Provides Business UpdatesNovember 24, 2025 7:05 AM EST | Source: NervGen Pharma Corp.Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injuryCompleted a U.S. Food and Drug Administration (FDA) Type C meeting in September; FDA confirmed that multiple regulatory routes are available to support approval of NVG-291 as ...

LAVAL, QC / ACCESS Newswire / November 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced the commencement of offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 (the "4.875% Notes") and 11.00% Senior Secured Notes due 2028 (the "11.00% Notes" and together with the 4.875% Notes, the "Existing Senior Secured Notes") for up to $1.6 billion aggregate principal amount (the "Maximum Notes Amount") of new 10.00% Senior Secur ...

Accessibility StatementSkip Navigation Veeva to deliver next generation customer engagement with agentic AI for Roche PLEASANTON, Calif., Nov. 24, 2025 /PRNewswire/ --Â Veeva Systems (NYSE: VEEV) today announced that Roche Pharmaceuticals has chosen to extend its partnership with Veeva Systems by adopting Veeva Vault CRM. "Roche and Veeva have partnered for many years," said Veeva CEO Peter Gassner. "We are honored to extend our partnership to Vault CRM and bring the next generation of AI-enabled CRM to the ...

AJ Bell Selects Northern Trust and Carne Group to Support Its In-House Fund Range Share Providing Solutions for £5bnofUK Investment Platform's Funds Under Management LONDON--(BUSINESS WIRE)--Northern Trust (Nasdaq: NTRS) and Carne Group (Carne) announce they are providing asset servicing and Authorised Corporate Director services respectively for AJ Bell, a United Kingdom (UK)-based asset manager and one of the country's leading investment platforms. AJ Bell has selected Northern Trust to provide custody, d ...

VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platformVBY329 meets Invivyd’s target profile of higher potency and improved barrier to resistance compared to standard of care RSV medicines, as assessed in vitro: Antiviral potency 1.5-fold greater on average than nirsevimab and 1.2-fold greater on average than clesrovimab against established authentic RSV strains rep ...

Beijing, China--(Newsfile Corp. - November 24, 2025) - iHuman Inc. (NYSE: IH), a leading provider of tech-powered, intellectual development products in China, today announced that its Investor Relations Director, Justin Zhang, will present at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL., on Wednesday, December 3rd at 12:00 PM Eastern Standard Time.Interested investors and guests of iHuman In ...

Namodenoson, a Phase III cancer drug has strong potential in veterinary oncology, a market projected to reach $3.1 billion by 2030 Piclidenoson is currently in development for the treatment of osteoarthritis in pets; Clinical studies show efficacy in dogs, representing a $3 billion market RAMAT GAN, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and in ...